Industry Faces Tough Road to Institutionalization of Key Premium, Eligibility Up for Discussion

The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) is determined to continue demanding that the government permanently introduce a key price premium system for new drug development in FY2016. The FPMAJ’s drug price study committee reiterated this intention to...read more